Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for ESK-001 in Moderate-to-severe plaque psoriasis. The expected timing is based on the latest available company guidance and may change.
05/14/26:- Ph3 ONWARD1/2 AAD data reported. ONWARD3/safety data H2 2026. NDA submission Q4 2026. 08/10/26:- ONWARD3 48-week PASI 100 was 54%. Remains on track for NDA submission in Q4 2026. 08/13/26:- ONWARD3 reported 54% PASI 100 at 48 weeks. Two-year safety data is expected in H2 2026. NDA submission will occur in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.